Literature DB >> 12431201

Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees.

M T Shata1, D D Anthony, N L Carlson, L Andrus, B Brotman, N Tricoche, P McCormack, A Prince.   

Abstract

The immune response to hepatitis C virus (HCV) is believed to be critical in determining the outcome of the disease. In this study we have analysed epitope recognition, cytokine profile, and anti-HCV antibody responses in chronically HCV-infected and recovered chimpanzees. Quantitative measurement of anti-HCV antibody in HCV-infected chimpanzees revealed that the response in HCV- recovered chimpanzees peaked within 4-20 weeks. In contrast, the anti-HCV antibody responses in chronically HCV infected chimpanzees did not peak until 100-200 weeks after infection, and decreased gradually thereafter. T cell proliferation assays measuring responses to pooled HCV proteins revealed significant increases in the 3H-uptake during the early stages of infection in recovered chimpanzees in comparison to the chronically infected ones. Class I-restricted epitopes of the core, and NS3 proteins of HCV were analysed using 9-10 mer overlapping peptides covering the core and NS3 proteins, and IFN-gamma ELISPOT technique. Our data indicated early and broad class-I restricted core, and NS3 protein epitope recognitions in HCV-recovered chimpanzees but not in chimpanzees that had been chronically infected. Additionally, dominant epitopes recognized early in infection (8 weeks) were no longer recognized later in infection (followed up to 64 weeks). Cytokines profiling revealed a 50-fold increase in TNF-alpha secretion in the supernatant of core-specific CD8 memory cells of the chronically infected chimpanzees in comparison to the recovered ones. In summary, multiple parameters correlate with HCV recovery in chimpanzees.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12431201     DOI: 10.1046/j.1365-2893.2002.00373.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  11 in total

1.  Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.

Authors:  Mohamed Tarek Shata; Nancy Tricoche; Marion Perkus; Darley Tom; Betsy Brotman; Patricia McCormack; Wolfram Pfahler; Dong-Hun Lee; Leslie H Tobler; Michael Busch; Alfred M Prince
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

Review 2.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

3.  Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees.

Authors:  Iryna Zubkova; Hongying Duan; Frances Wells; Howard Mostowski; Esther Chang; Kathleen Pirollo; Kris Krawczynski; Robert Lanford; Marian Major
Journal:  Hepatology       Date:  2014-01-28       Impact factor: 17.425

4.  Designing and Development of a DNA Vaccine Based On Structural Proteins of Hepatitis C Virus.

Authors:  Roghayeh Teimourpour; Amineh Sadat Tajani; Vahid Reza Askari; Sina Rostami; Zahra Meshkat
Journal:  Iran J Pathol       Date:  2016

5.  Parenchymal expression of CD86/B7.2 contributes to hepatitis C virus-related liver injury.

Authors:  Jiaren Sun; Batbayar Tumurbaatar; Junhui Jia; Hong Diao; Francis Bodola; Stanley M Lemon; Wendell Tang; David G Bowen; Geoffrey W McCaughan; Patrick Bertolino; Teh-Sheng Chan
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Schistosoma infection inhibits cellular immune responses to core HCV peptides.

Authors:  A Farid; M Al-Sherbiny; A Osman; N Mohamed; A Saad; M T Shata; D-H Lee; A M Prince; G T Strickland
Journal:  Parasite Immunol       Date:  2005-05       Impact factor: 2.280

Review 7.  Current progress in host innate and adaptive immunity against hepatitis C virus infection.

Authors:  Jijing Shi; Yuanyuan Li; Wenxian Chang; Xuexiu Zhang; Fu-Sheng Wang
Journal:  Hepatol Int       Date:  2017-06-22       Impact factor: 6.047

8.  Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.

Authors:  Kenneth E Sherman; Jeremie Guedj; Mohamed Tarek Shata; Jason T Blackard; Susan D Rouster; Mario Castro; Judith Feinberg; Richard K Sterling; Zachary Goodman; Bruce J Aronow; Alan S Perelson
Journal:  Sci Transl Med       Date:  2014-07-23       Impact factor: 17.956

9.  Characterization of hepatitis E-specific cell-mediated immune response using IFN-gamma ELISPOT assay.

Authors:  M T Shata; A Barrett; N J Shire; S F Abdelwahab; M Sobhy; E Daef; S S El-Kamary; M Hashem; R E Engle; R H Purcell; S U Emerson; G T Strickland; K E Sherman
Journal:  J Immunol Methods       Date:  2007-09-19       Impact factor: 2.303

10.  Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

Authors:  Ekaterina Alekseeva; Irina Sominskaya; Dace Skrastina; Irina Egorova; Elizaveta Starodubova; Eriks Kushners; Marija Mihailova; Natalia Petrakova; Ruta Bruvere; Tatyana Kozlovskaya; Maria Isaguliants; Paul Pumpens
Journal:  Genet Vaccines Ther       Date:  2009-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.